InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 29 November 2023

This study seeks to determine the appropriate dose level and effectiveness of combination targeted therapy (mirdametinib + BGB-3245) in people with advanced, metastatic or inoperable solid cancer who have had prior treatmentA Phase 1/2a Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination With BGB-3245 in Patients With Advanced Solid Tumors

Clinical summary

Summary

This study will be conducted in two sequential parts: Part 1 dose escalation and Part 2 dose expansion. In all arms, both mirdametinib and BGB-3245 will be administered orally.

Part 1 is enrolling people with an oncogenic mutation or other genomic aberration of the MPAK pathway who will be assigned to receive different dose levels to test their safety and effectiveness.

Part 2 has three cohorts that will enrol people with different types of cancer.

  • Part 2 Cohort A will recruit people with cutaneous melanoma harbouring NRAS mutations.
  • Part 2 Cohort B will recruit people with non-small cell lung cancer harbouring KRAS mutations.
  • Part 2 Cohort C will recruit people with non-small cell lung cancer or cutaneous melanoma harbouring BRAF Class II or Class III mutation or BRAF Fusion mutation.

Conditions

This trial is treating patients with advanced solid cancers

Cancer

Multi-Cancer Multi-Cancer

Age

People18+

Phase

I/II

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

SpringWorks Therapeutics, Inc

Scientific Title

A Phase 1/2a Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination With BGB-3245 in Patients With Advanced Solid Tumors

Eligibility

Inclusion

  • Able to provide informed consent
  • At least 18 years of age on day of signing ICF
  • Advanced, metastatic or unresectable solid cancer that has not responded to or progressed during or after at least 1 line of appropriate therapy or for which there is no treatment available or prior therapy was not tolerated.
  • Part 1: oncogenic mutation or other genomic aberration of the MAPK pathway
  • Part 2: oncogenic mutation or genomic aberration defined below:

    • Cohort A: cutaneous melanoma harboring NRAS mutations.
    • Cohort B: non-small cell lung cancer (NSCLC) harboring a KRAS mutation.
    • Cohort C: NSCLC or cutaneous melanoma harboring BRAF Class II or Class III mutations or BRAF Fusion mutation.
  • Must have archival tumor tissue or agree to a fresh tumor biopsy at screening
  • Measurable disease per RECIST 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
  • Adequate organ function and no transfusion within 14 days of first dose

Exclusion

  • Central Nervous System metastases, leptomeningeal carcinomatosis or untreated spinal cord compression
  • History of glaucoma
  • Active parathyroid disorder or history of malignancy associated hypercalcemia
  • Clinically significant cardiac disease within the past 6 months of signing ICF
  • History of toxicity from another RAF, MEK, ERK inhibitor requiring discontinuation of treatment from these agents
  • Severe or uncontrolled systemic disease
  • Inability to swallow oral medications
  • Clinically significant active infection (HIV, Hepatitis B or Hepatitis C)
  • History of or ongoing Immune Thrombocytopenia (ITP), Von Willebrand disease and/or other past or present bleeding disorders
  • Underlying medical conditions in investigator's opinion to be unfavorable to be a part of the study
  • Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose or anticipates need for major surgery while on study
  • Systemic anti-cancer therapy within 2 weeks or 5 half-lives before first dose
  • Concomitant systemic or glucocorticoid therapy within 2 weeks before first dose
  • Concomitant medicines that are strong CYP3A4 inhibitors or inducers within 2 weeks or 5 half-lives before first dose
  • Live vaccine within 4 weeks before first dose

Inclusion

  • You are able to swallow medication by mouth.
  • You have been diagnosed with cancer, but have not received any treatment.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.

Exclusion

  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.